Mr. Krause brings more than 25 years of experience in research, clinical development, commercialization, and corporate development in the biotech industry.

Mr. Krause most recently served as the Chief Strategy Officer of AN2 Therapeutics, Inc., a company applying boron chemistry to the discovery and development of novel therapies. In this role, he was the Project Team leader for AN2’s epetraborole Phase 2/3 NTM lung disease program, while overseeing various departments including Project Management, Clinical Operations, Regulatory, Quality, Medical Writing, and Corporate Development. Earlier in his career, he held various positions in R&D leadership and Corporate Business Development at Achaogen, Cerexa, and Theravance BioPharma where he was instrumental in the clinical development and/or approval of Zemdri® (plazomicin), Avycaz® (ceftazidime-avibactam), Emblaveo® (aztreonam-avibactam), Vibativ® (telavancin), Teflaro® (ceftaroline fosamil), Colobreathe® (inhaled colistin) and Quinsair® (inhaled levofloxacin).

Mr. Krause received an M.B.A. from the University of California, Berkeley Haas School of Business and a B.S. in Cell and Molecular Biology from San Francisco State University.

Alita is an expert in antibacterial discovery and development with over 25 years of experience in the field. Prior to joining ArrePath, she was Senior Vice President of Biology at Entasis Therapeutics, a company dedicated to the discovery and development of novel antibacterial agents to treat serious infections by resistant Gram-negative bacteria, including Xacduro® (sulbactam-durlobactam) and Nuzolvence® (zoliflodacin). Alita began her career at Pfizer where she led both large and small molecule antibacterial discovery projects and then moved to AstraZeneca, where she was Head of Microbial Genetics and Genomics before transitioning to Entasis. She has served on numerous Scientific Advisory Boards related to the field and is currently a member of Antimicrobial Agents and Chemotherapy’s editorial board.

Alita obtained a BA in chemistry from Kalamazoo College and worked as a chemist at both Merck and Eli Lilly before obtaining a PhD in Biochemistry and Molecular Biology from the University of Chicago. Her postdoctoral training was in the DiRita lab at the University of Michigan characterizing the molecular drivers of pathogenesis in Streptococcus pyogenes.

Kurt is a leader in the field of imaging and data sciences and , prior to joining ArrePath, was Senior Director Data Science at Zymergen, where he oversaw the building of a wide variety of data science tools, including statistical models for analysis of high throughput screening and fermentation data, recommendation algorithms for protein sequences catalyzing desired enzymatic functions and prediction of beneficial genetic edits for strain engineering, and chemical machine learning for predicting molecular properties from chemical structures.

Prior to Zymergen, Kurt spent 11 years at UCSF as an adjunct professor and director of the Nikon Imaging Center at UCSF/QB3, a highly successful light microscopy core facility, with 300 annual users and 40 papers published per year. He also ran an NIH-funded research lab that focused development of an integrated microscopy and microfluidic platform to enable highly multiplexed biochemical assays.

Kurt earned a bachelor’s degree in chemistry from Princeton University and a PhD in biophysics from UCSF, where he studied kinesin motility using single molecule imaging. Following UCSF, he was a fellow at the Bauer Center for Genomic Research at Harvard University, where he developed in vivo FRET bioassays.

Dylan Morris is a Managing Director at Insight. He joined the firm in 2021 to focus on investments in computational biology. Dylan was previously a general partner at CRV, where he built the bioengineering practice, leading the firm’s investments in Dyno Therapeutics, Recursion Pharmaceuticals, and Plexium, among others. Prior to CRV, Dylan invested at Innovation Endeavors, Eric Schmidt’s early stage venture capital firm, where he drove investments in companies operating at the intersection of data science and life science.

Before becoming an investor, Dylan cofounded Integrated Plasmonics, a venture-backed point-of-care diagnostics startup. Prior to that, he conducted graduate research in biochemistry and molecular biophysics at Caltech, where he co-authored multiple peer-reviewed publications. Dylan received his A.B. in Computer Science from Harvard University.

Venkat Srinivasan is a serial entrepreneur and investor. Innospark Ventures is an evergreen venture fund investing in early stage AI led startups. He brings deep expertise in AI and computational algorithms to the firm, especially natural language understanding, combined with deep functional knowledge in multiple domains including operations research, finance and accounting. He has founded several successful AI-led startups, including eCredit, Corporate Fundamentals and Rage Frameworks. More recently he has founded EnglishHelper (using AI to solve illiteracy at scale), Gyan.AI (first explainable natural language understanding engine), Creda Health (Digital Health Assistant for continuum of care) and PrismX (automated software development platform).

Venkat was honored with a Lifetime Achievement Award by The Indus Entrepreneurs [TiE] in 2017 (http://bit.ly/2j5ElGG). Dr. Srinivasan holds 9 patents, has published over 30 research papers in prestigious peer-reviewed journals, has co-edited two books and is the author of a book titled, The Intelligent Enterprise in the Era of Big Data (Wiley, 2017). Venkat has strongly advocated for and believes that successful AI-led transformation will be characterized by explainability, traceability, context awareness and the ability to learn from sparse data environments.

Prior to his entrepreneurial career, Venkat served as an Associate Professor at the D’More-McKim School of Business at Northeastern University.

As PhD holder in Cell & Molecular Biology, Detlev’s industrial career began in 2001 at metaGen & Schering. Joining Boehringer Ingelheim in 2005, he has steadily taken on roles of increasing responsibility. As a co-inventor & project leader, he contributed to the approval of Spevigo for the treatment of Generalized Pustular Psoriasis.

As Investment Director of the BI Venture Fund from 2014, he invested in groundbreaking therapeutics. He served on the boards of ViraTherapeutics & NBE Therapeutics until their respective acquisitions by Boehringer Ingelheim in 2018 & 2020.

In 2020, Detlev took charge as the Head of the Discovery Research unit Research Beyond Borders. By 2022, he had become the Head of Business Development & Licensing at Boehringer Ingelheim.